-
WilmerHale Represents Catch&Release in $14M Series A Financing
5.5.2021On April 20, 2021, Catch&Release, a creative technology company for the next generation of commercial production, announced it has secured $14 million in Series A funding to help brands break free from the limitations of stock photography.
-
WilmerHale Advises Datanomix in $6M Series A Funding Round
5.4.2021On May 4, 2021, Datanomix, leading vendor of production intelligence software for industrial manufacturers, announced it has raised $6 million in Series A funding.
-
2021 IPO, Venture Capital and M&A Reports
4.26.2021WilmerHale’s annual IPO, Venture Capital and M&A Reports offer insights into market conditions and provide comprehensive statistics and analysis that are hard to find elsewhere.
-
2021 M&A Report
4.26.2021The 2021 M&A Report provides a detailed global M&A market review and outlook, as well as insights on key topics.
-
2021 IPO Report
4.26.2021The 2021 IPO Report offers a detailed IPO market review and outlook, plus useful market metrics and articles on topics of interest for pre-IPO companies.
-
2021 Venture Capital Report
4.26.2021The 2021 Venture Capital Report offers an in-depth US venture capital market review and outlook, including industry and regional breakdowns, as well as insights on a number of key topics.
-
WilmerHale Represents ExecOnline in $45M Series D Funding Round
4.21.2021ExecOnline, the pioneer of online leadership development for enterprises, announced a Series D funding round of $45 million led by OMERS Growth Equity.
-
WilmerHale Advises Volastra Therapeutics in Extended $44M Seed Financing
4.6.2021On April 6, 2021, Volastra Therapeutics, a biotechnology company developing novel therapies for the prevention and treatment of metastatic cancer, announced the extension of its original $12 million seed round to a total of $44 million.
-
Recent Venture Financings as Company Counsel: 2021
3.5.2021In 2020, we served as counsel in more than 200 venture financings raising in excess of $10 billion, including some of the largest and most prominent deals of the year. Since 2010, we have handled approximately 2,700 venture financings with total proceeds in excess of $48 billion.
-
WilmerHale Advises Xilio Therapeutics In $95M Series C Financing
2.25.2021On February 24, 2021, Xilio Therapeutics, a biotechnology company developing potent, tumor-selective immunotherapies for patients with cancer, announced the successful closing of a $95 million Series C financing round.
-
WilmerHale Advises Orna Therapeutics in $80M Series A Financing
2.24.2021On February 24, 2021, Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA therapeutics (oRNAs), announced the completion of its $80 million Series A financing.
-
WilmerHale Represents WizeHire in $7.5M Series A Financing
2.19.2021On February 9, 2021, WizeHire, a user-friendly, effective hiring solution for small businesses, announced the closing of $7.5 million in Series A funding.
-
WilmerHale Advises Esme Learning Solutions in $7.5M Series A Financing
1.27.2021Esme Learning Solutions, a leading digital learning platform, announced the close of a $7.5 million Series A financing round led by Adit Ventures, a venture capital firm with a technology thematic investment focus.
-
WilmerHale Represents Verve Therapeutics in $94M Series B Financing
1.22.2021On January 19, 2021, Verve Therapeutics, a biotech company pioneering gene editing medicines to treat cardiovascular disease, announced the successful completion of a $94 million Series B financing.
-
WilmerHale Advises Werewolf Therapeutics in $72M Series B Financing
1.8.2021On January 7, 2021, Werewolf Therapeutics, an oncology biotherapeutics company advancing a pipeline of next-generation, transformative cancer treatments, announced the completion of its $72 million Series B financing.
